Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth
Executive Summary
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.
You may also be interested in...
Bausch + Lomb Micronizes Lutein, Zeaxanthin In PreserVision OCUSorb
PreserVision AREDS 2 mini-softgel has proprietary OCUSorb formulation with micronized ingredients in a medium-chain triglyceride oil. More than line extensions, though, are needed for B+L to shed influence from Bausch Health’s credit rating.
Bausch + Lomb’s First Results Look Familiar
January-March results Bausch + Lomb reported on 8 June were included in Bausch Health’s results published in May on the same day it closed an IPO shares to separate its eye health and vision care business. Guidance it provided, however, was new and a first for Bausch + Lomb.
Familiar Leadership For J&J's Planned Consumer Spinoff
J&J's current consumer health division head, Thibaut Mongon, will be at the helm of its planned spinout of the business while Paul Ruh will move to the company was CFO.